A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair.
about
The Bone Marrow-Derived Stromal Cells: Commitment and Regulation of AdipogenesisMicroRNA-433-3p promotes osteoblast differentiation through targeting DKK1 expressionSuppression of Sclerostin Alleviates Radiation-Induced Bone Loss by Protecting Bone-Forming Cells and Their Progenitors Through Distinct Mechanisms.Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myelomaBispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Investigational anabolic agents for the treatment of osteoporosis: an update on recent developments.The Lrp4R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans.Role and mechanism of action of sclerostin in bone.The skeletal cell-derived molecule sclerostin drives bone marrow adipogenesis.Fracture healing physiology and the quest for therapies for delayed healing and nonunion.One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.Osteoporosis treatment: recent developments and ongoing challenges.Molecular genetics and targeted therapy of WNT-related human diseases (Review).Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer.Reduced β-catenin expression affects patterning of bone primordia, but not bone maturation.The making of bispecific antibodiesHeterozygous deletion of both sclerostin (Sost) and connexin43 (Gja1) genes in mice is not sufficient to impair cortical bone modeling.A WNT protein therapeutic improves the bone-forming capacity of autografts from aged animals.Cushioning the cartilage: a canonical Wnt restricting matter.Bone Loss in Rheumatoid Arthritis: Basic Mechanisms and Clinical Implications.Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.Bone-Targeted Therapies in Cancer-Induced Bone Disease.A systematic review of current osteoporotic metaphyseal fracture animal models.Bispecific antibodies: design, therapy, perspectives.Homozygous Dkk1 Knockout Mice Exhibit High Bone Mass Phenotype Due to Increased Bone Formation.Sclerostin expression and functions beyond the osteocyte.Bone diseases: Dual sclerostin-DKK1 antibody outperforms monotherapy.Association of Circulating Wnt Antagonists With Severe Abdominal Aortic Calcification in Elderly Women.Sclerostin Blockade-A Dual Mode of Action After All?Anabolic Strategies to Augment Bone Fracture Healing.Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic StrategyRethinking Bone Disease in Kidney Disease
P2860
Q28078585-14A37CB4-DD2D-40F0-ADC8-BEC658237104Q33811916-A8636703-A575-4AF4-A78D-2C1E6E8932C0Q33812106-AFC69AAF-5727-419B-97A3-3B82DAC00838Q33856318-AFCA43C1-4137-45EE-B6E8-DDF16C34DF9AQ34548319-FA827E27-D85D-443C-BD79-C2278513F8B6Q38610545-B0974DA9-4F1A-4DE2-85F4-7593100292BAQ38687054-B938C052-FA0C-4C31-9E0C-CA0D990E9178Q38807230-0504F46F-9187-4B09-92C7-8B4827888A60Q38810794-EDE7B5F8-1BBF-4C72-B4D1-3A9F77B6A817Q38981442-880624CF-5920-47D4-8525-E217707DB4D3Q39283452-097D9C5F-7BE6-42F2-8D73-D288C64D55BEQ39423904-682FA5C0-2053-4F2A-814E-481130BBF100Q39450241-A4D5D54C-4D46-4BDB-AEC6-62BF74F3FA2BQ41194152-2AA0387B-7934-42CE-BB2C-A43283BB88C5Q42206599-8E8AF342-9985-429D-997B-12C45EA40EFAQ42323236-ABD4DB99-A3FF-4865-81C0-16A41BBAC91EQ47165519-1A6FD8F1-6132-413F-B453-C03DD912B544Q47192623-C8FFA56E-D597-4DE4-8EB9-FC50BBEAABA0Q47578652-3423AD14-395A-4DD8-B1B5-3DDAFB0E28DFQ47800990-8D1155A5-05C8-4A6C-8969-28451B997B3AQ47909734-5C04A3DB-101E-4803-A63F-6487AF417EB6Q48110513-410DDE26-6DE7-4E0A-B616-2A7C88FF4B54Q49164667-A9D5B51B-E8F0-4F90-8210-48E8FC6B52C2Q49195146-46410754-0AF8-4ED6-A34E-115A5A0E8761Q50145648-F9FFE382-F1CF-4165-97FF-CF9569C64F7EQ51303428-2C4F279C-BFE6-40A3-A77D-8481D0375F85Q51698693-9062281C-9AF4-4CB1-9189-99B3B345EFC5Q51776576-C49EAB91-82F4-4AD2-9DA1-7EE6CB8B2E54Q54035461-E1FCBE0A-FE88-412A-99BD-FFC8B32E4B10Q55411806-012E140F-8E3A-4A07-909C-B6D3C1A90D97Q58566593-5328FF71-7640-465E-BD43-CF897361E9CDQ59126536-32F9ED36-D886-41FC-9868-7373B3120029
P2860
A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
A bispecific antibody targetin ...... s accrual and fracture repair.
@en
type
label
A bispecific antibody targetin ...... s accrual and fracture repair.
@en
prefLabel
A bispecific antibody targetin ...... s accrual and fracture repair.
@en
P2093
P2860
P356
P1476
A bispecific antibody targetin ...... s accrual and fracture repair.
@en
P2093
Amy N Duguay
Banghua Sun
Barbara Tipton
Brenda Heron
Brian D Soriano
Chaoyang Li
Chun-Ya Han
Efrain Pacheco
Emil Brisan
Franklin J Asuncion
P2860
P2888
P356
10.1038/NCOMMS11505
P407
P577
2016-05-27T00:00:00Z